BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bryan Oncor, Inc. Reports Positive Phase I Results for Its New Targeted Lung Cancer Therapy


12/21/2009 10:03:40 AM

Bookmark and Share

BOSTON, MA--(Marketwire - December 21, 2009) -

Bryan Oncor reports the results of a Phase I trial of its targeted radiopharmaceutical therapy using Re-88 P2045, a radiolabeled synthetic peptide, for the treatment of advanced lung cancer. The trial was conducted at the University of Maryland and the University of Iowa and published in the December issue of the Journal of Thoracic Oncology.

This novel approach to cancer treatment combines a synthetic peptide molecule, P2045, which targets over expressed somatostatin receptors (SSTR) on tumors, with a radioactive isotope, Re-188, which has been shown to destroy cancer cells.

The trial results demonstrate that Re-188 P2045 is well tolerated, and that targeting SSTRs using this approach is feasible. Martin Magram, MD, an author of the published paper, comments, "This targeted, personalized approach to therapy has the potential to treat a large unmet need in cancer treatment. Somatostatin receptors are expressed not only in lung cancer, but in several other types of tumors, as well."

This targeted approach can reduce the risk of toxicity to patients in two ways. First, it enables screening to determine which patients are most likely to benefit from the treatment. Second, because the radiolabeled peptide is bound to the SSTRs on the cancer cells, the dose is concentrated at the tumor site. While the Re-188 P2045 is retained at the tumor, it clears quickly from the blood, minimizing "off-target" systemic exposure.

All of the patients in the trial had advanced lung cancer and entered the study with progressive disease. Over half of the patients had stable disease at eight weeks with overall survival of more than 11 months.

"We're very encouraged by the results of the Phase I trial, and are planning further studies to demonstrate the effectiveness of targeted RE-P2045 therapy," said Christopher Adams, co-founder of Bryan Oncor.

Bryan Oncor develops innovative cancer therapies that target specific cancers to maximize potential treatment benefits while minimizing risk of toxicity. The company has exclusive worldwide rights to the radiolabeled peptide P2045, its backups and analogs. www.bryanoncor.com.


Contact:
Christopher P. Adams
CEO
617-273-2466
info@bryanoncor.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->